-
公开(公告)号:US20180118853A1
公开(公告)日:2018-05-03
申请号:US15792373
申请日:2017-10-24
Applicant: UCB PHARMA S.A.
Inventor: David Paul Humphreys , Emma Dave , Laura Griffin , Sam Philip Heywood
CPC classification number: C07K16/468 , C07K16/00 , C07K16/18 , C07K16/245 , C07K2317/24 , C07K2317/31 , C07K2317/522 , C07K2317/54 , C07K2317/55 , C07K2317/569 , C07K2317/64 , C07K2317/92
Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
-
公开(公告)号:US09925260B2
公开(公告)日:2018-03-27
申请号:US13934433
申请日:2013-07-03
Applicant: UCB PHARMA S.A.
Inventor: Martyn Kim Robinson
CPC classification number: A61K39/3955 , A61K33/42 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/22 , C07K2317/94
Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
-
公开(公告)号:US09631015B2
公开(公告)日:2017-04-25
申请号:US14795374
申请日:2015-07-09
Applicant: UCB Pharma S.A.
Inventor: Richard Evan Gelinas , Mitra Choudhury Singhal , Yi Zhang , Andrew George Popplewell , Ralph Adams
IPC: A61K39/395 , C07K16/24 , A61K39/00
CPC classification number: A61K39/3955 , A61K2039/505 , C07K16/248 , C07K2316/96 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N15/11
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号:US20160200810A1
公开(公告)日:2016-07-14
申请号:US15083446
申请日:2016-03-29
Applicant: UCB PHARMA, S.A.
Inventor: MARK ELLIS , DAVID PAUL HUMPHREYS
IPC: C07K16/24
CPC classification number: C12N1/20 , C07K16/241 , C07K16/244 , C07K2317/14 , C07K2317/20 , C07K2317/55 , C12N9/52 , C12N15/70 , C12P21/02 , C12R1/19 , Y02P20/52
Abstract: A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a) a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b) a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c) a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated DegP gene and optionally a polynucleotide sequence encoding a protein of interest.
-
公开(公告)号:US09387212B2
公开(公告)日:2016-07-12
申请号:US14395533
申请日:2013-04-19
Applicant: UCB Pharma S.A.
Inventor: Anne Michel , Patrick Downey , Florian Montel , Dieter Scheller , Bernard Christophe
IPC: A61K31/5377 , A61K31/195 , A61K31/198 , A61K31/445 , A61K31/451 , A61K31/495 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/52 , A61K31/423 , A61K31/5415 , A61K45/06 , A61K31/454
CPC classification number: A61K31/522 , A61K9/20 , A61K31/195 , A61K31/198 , A61K31/423 , A61K31/445 , A61K31/451 , A61K31/454 , A61K31/495 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/52 , A61K31/5377 , A61K31/5415 , A61K45/06 , A61K2300/00
Abstract: The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A2A) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B.
Abstract translation: 本发明涉及一种治疗哺乳动物帕金森病(PD)的方法,包括施用第一药剂和第二药剂,其中第一药剂是腺苷受体2(A2A)和第二药剂的拮抗剂 是N-甲基-D-天冬氨酸(NMDA)受体亚型NR2B的拮抗剂。
-
公开(公告)号:US20150150979A1
公开(公告)日:2015-06-04
申请号:US14406758
申请日:2013-06-20
Applicant: UCB PHARMA, S.A.
Inventor: Andrew Jeffrey Yates , James Gregory Clipstone
CPC classification number: A61K47/12 , A61K9/0019 , A61K39/3955 , A61K39/39591 , A61K47/02 , A61K47/183 , A61K47/26 , C07K16/2803 , C07K2317/24
Abstract: The present invention relates to methods and means for reducing the viscosity of a pharmaceutical formulation comprising an antibody or other therapeutic protein at a high concentration. The present invention provides a liquid pharmaceutical formulation comprising an antibody at a high concentration with reduced viscosity that does not impede processing or injection of the pharmaceutical formulation.
Abstract translation: 本发明涉及降低包含高浓度的抗体或其它治疗性蛋白质的药物制剂的粘度的方法和方法。 本发明提供一种液体药物制剂,其包含高浓度的抗体,其具有降低的粘度,其不妨碍药物制剂的加工或注射。
-
公开(公告)号:US09040048B2
公开(公告)日:2015-05-26
申请号:US13672077
申请日:2012-11-08
Applicant: UCB PHARMA S.A.
Inventor: Ralph Adams , Pallavi Bhatta , Sam Philip Heywood , David Paul Humphreys
IPC: A61K39/395 , C07K14/705 , C07K16/28 , C07K16/18 , A61K39/00
CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K16/2878 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/624 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract translation: 本发明涉及对人OX40的抗原决定簇具有特异性的抗体分子,抗体分子的治疗用途以及产生所述抗体分子的方法。
-
公开(公告)号:US08986954B2
公开(公告)日:2015-03-24
申请号:US14285721
申请日:2014-05-23
Applicant: UCB Pharma S.A.
Inventor: Helene Margaret Finney , Terence Seward Baker , Alastair David Griffiths Lawson , Karen Margrete Miller , Marc Roger de Ryck , Christian Gilbert J. Wolff
CPC classification number: C07K16/28 , A61K39/3955 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76
Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
Abstract translation: 结合后的Nav1.7结合实体功能性地修饰离子通道的活性,特别是抗Nav1.7抗体或其结合片段,包含所述抗体的药物组合物,使用抗体及其组合物在治疗中 ,例如在疼痛的治疗/调节中以及产生和制备所述抗体的方法。
-
89.
公开(公告)号:US08986685B2
公开(公告)日:2015-03-24
申请号:US13644728
申请日:2012-10-04
Applicant: UCB Pharma S.A.
Inventor: Mary E. Brunkow , David J. Galas , Brian Kovacevich , John T. Mulligan , Bryan W. Paeper , Jeffrey Van Ness , David G. Winkler
IPC: A61K39/395 , C07K16/18 , C12P21/08 , A61K45/06 , C07K14/51 , C07K16/22 , C12Q1/68 , G01N33/68 , A61K48/00
CPC classification number: G01N33/74 , A01K2217/05 , A01K2217/075 , A61K38/18 , A61K39/3955 , A61K45/06 , A61K48/00 , C07K14/475 , C07K14/51 , C07K16/18 , C07K16/22 , C07K2317/11 , C07K2317/23 , C07K2319/00 , C12N2799/021 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N33/6872 , G01N33/84 , G01N2333/47 , G01N2333/495 , G01N2333/51 , G01N2500/02 , G01N2500/20
Abstract: Described herein are pharmaceutical compositions comprising an anti-sclerostin antibody and an inhibitor of bone resorption.
Abstract translation: 本文描述了包含抗硬化蛋白酶抗体和骨吸收抑制剂的药物组合物。
-
公开(公告)号:US20140315885A1
公开(公告)日:2014-10-23
申请号:US14357340
申请日:2012-11-08
Inventor: Daniel Christopher Brookings , Daniel James Ford , Richard Jeremy Franklin , Anant Ramrao Ghawalkar , Claire Louise Kulisa , Judi Charlotte Neuss , James Thomas Reuberson
IPC: C07D513/04 , C07D519/00
CPC classification number: C07D513/04 , A61K31/519 , C07D519/00
Abstract: A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.
Abstract translation: 一系列式(I)的噻唑并[5,4-d]嘧啶衍生物或其N-氧化物,或其药学上可接受的盐或溶剂化物:(I)Q表示式(Qa),(Qb) ,(Qc),(Qd)或(Qe)有利于治疗和/或预防各种人类疾病,包括炎症,自身免疫和肿瘤疾病; 病毒性疾病 和器官和细胞移植排斥反应。
-
-
-
-
-
-
-
-
-